Boston Scientific Announces FDA Clearance and U.S. and European Availability of WallFlex(R) Biliary RX Cove...(n a 70-patient WallFlex Biliary RX parti...),Health

Date:10/6/2009

n a 70-patient WallFlex Biliary RX partially covered stent study led by Primary Investigator Guido Costamagna, M.D., Head of Digestive Endoscopy at Universita Cattolica del Sacro Cuore in Rome. Preliminary results of the study demonstrate that the partially covered metal stent may palliate most patients with malignant biliary obstructions.

Pancreatic cancer is the most common cause of malignant biliary obstructions with 250,000 new cases diagnosed worldwide each year. Most patients have less than six months to live after diagnosis(3). Other causes of malignant biliary obstructions include bile duct, liver and gallbladder cancer. Approximately 70 percent of patients with a malignant bile duct obstruction are poor candidates for surgery because the cancer has spread (4). With these cases, palliative treatment can improve the patient's quality of life by controlling the symptoms and complications of the disease.

The safety and effectiveness of the WallFlex Biliary RX Stenting System for use in the vascular system have not been established.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

About Boston Scientific Endoscopy

Boston Scientific Endoscopy develops innovative technology for less invasive, more efficient gastrointestinal procedures.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statemen
'/>"/>

SOURCE Boston Scientific Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts
2. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
3. The 60th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA -- Hynes Convention Center October 31 -- November 3, 2009
4. SPIRIT IV Results Reaffirm Strong Performance of Boston Scientific PROMUS(R) and TAXUS(R) Express(R) Stents
5. Boston Scientific Announces Schedule for European Society of Cardiology Congress
6. Boston Scientific Welcomes Results of Brain Aneurysm Clinical Trial
7. Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease
8. Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
9. Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
10. Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientifics TAXUS(R) Liberte(R) Stent
11. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine